Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.12EUR
−49.09 MEUR
91.89 MEUR
89.55 M
About BIOCYTOGEN PHARMACEUTICALS (BEIJING
Sector
CEO
Yue Lei Shen
Website
Headquarters
Beijing
Employees (FY)
1.07 K
Founded
2009
ISIN
CNE100005D27
FIGI
BBG019JBQWR6
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. manufactures biological products and provides related biological services. It operates through the following segments: Gene Editing Services, Pre-Clinical Pharmacology and Efficacy Evaluation, Animal Models Selling, Antibody Development, and Innovative Drugs Development. The Gene Editing Services segment provides gene editing services. The Pre-Clinical Pharmacology and Efficacy Evaluation segment involves in the provision of pre-clinical pharmacology service for drug efficacy and toxicity evaluation. The Animal Models Selling segment breeds and sells the animal models for the external and internal use. The Antibody Development segment includes one-stop solution from antibody preparation to IND filing for the customer. The Innovative Drugs Development consists of research and developing drugs with a focus on oncology and autoimmune disease therapeutics. The company was founded by Yue Lei Shen on November 13, 2009 and is headquartered in Beijing, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of I54 is 1.06 EUR — it hasn't changed in the past 24 hours. Watch BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. stocks are traded under the ticker I54.
I54 stock has fallen by 8.62% compared to the previous week, the last month showed zero change in price, over the last year BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. has showed a 62.41% decrease.
We've gathered analysts' opinions on BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. future price: according to them, I54 price has a max estimate of 1.93 EUR and a min estimate of 1.72 EUR. Watch I54 chart and read a more detailed BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. stock forecast: see what analysts think of BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. and suggest that you do with its stocks.
I54 stock is 0% volatile and has beta coefficient of 0.76. Track BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. stock price on the chart and check out the list of the most volatile stocks — is BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. there?
Today BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. has the market capitalization of 409.93 M, it has decreased by 9.09% over the last week.
Yes, you can track BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. financials in yearly and quarterly reports right on TradingView.
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. is going to release the next earnings report on Aug 27, 2024. Keep track of upcoming events with our Earnings Calendar.
I54 earnings for the last quarter are −0.06 EUR per share, whereas the estimation was −0.06 EUR resulting in a −9.09% surprise. The estimated earnings for the next quarter are −0.05 EUR per share. See more details about BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. earnings.
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. revenue for the last quarter amounts to 49.78 M EUR despite the estimated figure of 46.93 M EUR. In the next quarter revenue is expected to reach 50.60 M EUR.
I54 net income for the last quarter is −24.20 M EUR, while the quarter before that showed −25.11 M EUR of net income which accounts for 3.60% change. Track more BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. financial stats to get the full picture.
No, I54 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 1, 2024, the company has 1.07 K employees. See our rating of the largest employees — is BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. EBITDA is −16.41 M EUR, and current EBITDA margin is −17.78%. See more stats in BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. financial statements.
Like other stocks, I54 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. stock shows the sell signal. See more of BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.